J&J results
This article was originally published in The Tan Sheet
Executive Summary
Worldwide consumer health sales grew 9.9% to $2 bil. in the third quarter, with U.S. sales up 4% to roughly $1 bil. and international sales up 16.8% to $1 bil., J&J reports in an Oct. 12 earnings call. The firm cited Neutrogena skin care products as well its wound care business as strong contributors. Domestic sales were affected by the divestiture of the Splenda business, while international results included a continued impact from the acquisition of Merck's stake in the firms' joint European nonprescription business (1"The Tan Sheet" April 26, 2004. p. 6). McNeil's sales growth of 13% was primarily attributable to international sales...
You may also be interested in...
J&J Buyout Of Merck Stake In Europe Was In The Works “For Some Time”
Retaining rights to future Rx-to-OTC switches and a substantial one-time cash infusion were the major drivers of Merck's decision to sell its 50% stake of an OTC venture in Europe to partner Johnson & Johnson
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.